Armando Peixoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Armando Peixoto has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Guilherme Macedo
Department of Gastroenterology, São João University Hospital, 4200-319 Porto, Portugal
50 shared publications Pedro Pereira
Gastroenterology Department, Centro Hospitalar de São João;Oporto WGO Training Center; Porto Medical School, University of Porto, Porto, Portugal
14 shared publications- Marco Silva
Gastroenterology Department, Centro Hospitalar São João, Porto, Portugal
13 shared publications Marco Silva
Department of Gastroenterology, Centro Hospitalar de São João, Porto, Portugal
10 shared publications- Eduardo Rodrigues-Pinto
Gastroenterology Department, Centro Hospitalar Universitário de São João, Porto, Portugal
5 shared publications - Fernando Magro
Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal
5 shared publications
Latest Publications
- Open Access
- 21 April 2025
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- p. 1-27
Rifaximin as a Therapeutic Ally in the Modulation of Dysbiosis: A Narrative Review of Its Applicability in Gastrointestinal Disorders
Background: The gastrointestinal microbiota is vital for a well-functioning digestive tract, nutrient metabolism, immune support and protection against pathogenic microorganisms. Disruption of this balance is known as dysbiosis. Rifaximin, an oral antibiotic with selective action, reduces harmful gut bacteria while preserving beneficial species, aiding in microbiota restoration. Summary: Alterations in the intestinal microbiota are implicated in many gastrointestinal disorders. Rifaximin, by targeting and modulating the microbiota, may serve as a powerful tool in the approach of these conditions. Key Messages: This narrative review summarizes the main uses of rifaximin in gastrointestinal disorders like Irritable Bowel Syndrome, Diverticular Disease, Small Intestinal Bacterial Overgrowth, Traveler’s Diarrhea, Hepatic Encephalopathy, Clostridioides Difficile Infection and Inflammatory Bowel Disease.
- 21 April 2025
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- p. 1-27
Open AccessRifaximin as a Therapeutic Ally in the Modulation of Dysbiosis: A Narrative Review of Its Applicability in Gastrointestinal Disorders
Background: The gastrointestinal microbiota is vital for a well-functioning digestive tract, nutrient metabolism, immune support and protection against pathogenic microorganisms. Disruption of this balance is known as dysbiosis. Rifaximin, an oral antibiotic with selective action, reduces harmful gut bacteria while preserving beneficial species, aiding in microbiota restoration. Summary: Alterations in the intestinal microbiota are implicated in many gastrointestinal disorders. Rifaximin, by targeting and modulating the microbiota, may serve as a powerful tool in the approach of these conditions. Key Messages: This narrative review summarizes the main uses of rifaximin in gastrointestinal disorders like Irritable Bowel Syndrome, Diverticular Disease, Small Intestinal Bacterial Overgrowth, Traveler’s Diarrhea, Hepatic Encephalopathy, Clostridioides Difficile Infection and Inflammatory Bowel Disease.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Pesquisa Brasileira em Odontopediatria e Clínica Integrada
- Vol. 25, e230008
Evaluation of the Confidence Levels in Treatment Planning Decisions among Dental Students
Objective: To evaluate confidence levels in treatment planning decisions among dental students.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Pesquisa Brasileira em Odontopediatria e Clínica Integrada
- Vol. 25, e230008
Open AccessEvaluation of the Confidence Levels in Treatment Planning Decisions among Dental Students
Objective: To evaluate confidence levels in treatment planning decisions among dental students.
- 17 November 2023
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (3) , 412
Gelée Blanche
An abstract is unavailable. This article is available as a PDF only.
- 17 November 2023
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (3) , 412
Gelée Blanche
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 22 June 2023
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 32 (2) , 257-260
A Rare Case of Autoimmune Enteropathy Associated with Autoimmune Hepatitis
A 74-year-old woman was admitted for weight loss, abdominal pain and diarrhea for a year. Blood tests showed elevated transaminases, cholestasis and hyperbilirubinemia. Capsule endoscopy revealed extensively scattered lymphangiectasias, shortened villi and erosions in the jejunum and ileum. The histological examination of the small bowel mucosa biopsies evidenced severe mucosal atrophy and crypt hyperplasia, without significant intraepithelial lymphocytosis. The clinical picture, lack of response to a gluten-free diet and endoscopic and histopathologic findings were compatible with autoimmune enteropathy. Simultaneously, autoimmune hepatitis was also diagnosed. The patient showed significant improvement after starting treatment with prednisolone and azathioprine. To our knowledge, this is the first case of autoimmune enteropathy diagnosed simultaneously with autoimmune hepatitis.
- 22 June 2023
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 32 (2) , 257-260
Open AccessA Rare Case of Autoimmune Enteropathy Associated with Autoimmune Hepatitis
A 74-year-old woman was admitted for weight loss, abdominal pain and diarrhea for a year. Blood tests showed elevated transaminases, cholestasis and hyperbilirubinemia. Capsule endoscopy revealed extensively scattered lymphangiectasias, shortened villi and erosions in the jejunum and ileum. The histological examination of the small bowel mucosa biopsies evidenced severe mucosal atrophy and crypt hyperplasia, without significant intraepithelial lymphocytosis. The clinical picture, lack of response to a gluten-free diet and endoscopic and histopathologic findings were compatible with autoimmune enteropathy. Simultaneously, autoimmune hepatitis was also diagnosed. The patient showed significant improvement after starting treatment with prednisolone and azathioprine. To our knowledge, this is the first case of autoimmune enteropathy diagnosed simultaneously with autoimmune hepatitis.
- Open Access
- 17 December 2022
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 31 (4) , 476-477
Buried bumper syndrome: incidence study and clinical characterization of a rare complication of percutaneous endoscopic gastrostomy
- 17 December 2022
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 31 (4) , 476-477
Open AccessBuried bumper syndrome: incidence study and clinical characterization of a rare complication of percutaneous endoscopic gastrostomy
- Open Access
- 1 January 2022
- Published by Sociedad Espanola de Patologia Digestiva (SEPD) in Revista Española de Enfermedades Digestivas
- Vol. 114 (7) , 434
The long life of a hemoclip
An 87-year-old male with frequent episodes of food impaction underwent esophageal high-resolution manometry, which revealed type-I achalasia. Due to his advanced age and the presence of comorbidities, botulinum toxin injection was proposed and accepted by the patient. In June 2021, esophagogastroduodenoscopy revealed an esophageal dilatation with liquid and food retention and narrowing of the esophagogastric junction. An injection of 25 units of botulinum toxin diluted in 10 mL of saline was administered in each of the 4 lower esophageal sphincter quadrants, with no complications.
- 1 January 2022
- Published by Sociedad Espanola de Patologia Digestiva (SEPD) in Revista Española de Enfermedades Digestivas
- Vol. 114 (7) , 434
Open AccessThe long life of a hemoclip
An 87-year-old male with frequent episodes of food impaction underwent esophageal high-resolution manometry, which revealed type-I achalasia. Due to his advanced age and the presence of comorbidities, botulinum toxin injection was proposed and accepted by the patient. In June 2021, esophagogastroduodenoscopy revealed an esophageal dilatation with liquid and food retention and narrowing of the esophagogastric junction. An injection of 25 units of botulinum toxin diluted in 10 mL of saline was administered in each of the 4 lower esophageal sphincter quadrants, with no complications.
- Open Access
- 1 January 2022
- Published by Sociedad Espanola de Patologia Digestiva (SEPD) in Revista Española de Enfermedades Digestivas
- Vol. 114 (7) , 425-+
Clinical and endoscopic findings in gastrointestinal amyloidosis: a single-center experience
Gastrointestinal involvement occurs in approximately 4% of cases of systemic amyloidosis. The most common site of amyloid deposition is small bowel, followed by stomach, colorectum and esophagus. Although rare, gastrointestinal amyloidosis may be associated with severe complications including gastrointestinal bleeding or perforation and may be mistaken for malignancy.
- 1 January 2022
- Published by Sociedad Espanola de Patologia Digestiva (SEPD) in Revista Española de Enfermedades Digestivas
- Vol. 114 (7) , 425-+
Open AccessClinical and endoscopic findings in gastrointestinal amyloidosis: a single-center experience
Gastrointestinal involvement occurs in approximately 4% of cases of systemic amyloidosis. The most common site of amyloid deposition is small bowel, followed by stomach, colorectum and esophagus. Although rare, gastrointestinal amyloidosis may be associated with severe complications including gastrointestinal bleeding or perforation and may be mistaken for malignancy.
- Open Access
- 15 January 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (Supplement) , S643
P829 Methylation patterns in dysplasia in inflammatory bowel disease patients
Inflammatory Bowel Disease (IBD) with colonic involvement increases colorectal cancer risk. However, the distinction between IBD related and sporadic dysplasia in IBD patients is difficult. Some data favours the importance of abnormal DNA methylation in IBD-related carcinogenesis. Our study aimed to define methylation patterns in patients with a colonic cancer or dysplasia diagnosis following an IBD diagnosis. Multicentric cross-sectional study- 91 samples from colonic mucosa with/without dysplasia from 9 patients with IBD-related dysplasia/cancer and 26 patients with IBD and sporadic dysplasia/cancer were included. Methylation patterns of CpG islands in the promoter regions of 67 genes were studied by Methylation-specific Multiplex Ligation-dependent Probe Amplification. Mean age at IBD diagnosis: 42±16 years; at dysplasia diagnosis: 56± ± 14 years. Twenty-nine patients had ulcerative colitis. Twenty-five patients had at least 1 lesion endoscopically described as adenoma-like, 4 at least 1 non-adenoma like, 3 had cancer and 3 had dysplasia in flat mucosa. No patient had both adenoma-like and non-adenoma-like lesions. Patients with an IBD-related lesion were significantly younger at IBD diagnosis (p = 0.003) and at dysplasia/cancer diagnosis (p = 0.039). Promoter methylation of IGF2, RARB, ESR1, CHFR, CDH13, WT1, GATA5, WIF1 genes was significantly associated to dysplasia/cancer; methylation of MSH6, TIMP3 was significantly associated to IBD-related dysplasia/cancer. Promoter methylation of MSH6, MSH3, RUNX3, CRABP1, TP73, RARB, CDH13, PAX5, WT1, THBS1, TP53, SFRP1, WIF1, APAF1, BCL2 genes was significantly associated to active IBD. Methylation analysis, namely of MSH6, may contribute to the classification of dysplastic lesions in IBD– to be further tested in prospective studies.
- 15 January 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (Supplement) , S643
Open AccessP829 Methylation patterns in dysplasia in inflammatory bowel disease patients
Inflammatory Bowel Disease (IBD) with colonic involvement increases colorectal cancer risk. However, the distinction between IBD related and sporadic dysplasia in IBD patients is difficult. Some data favours the importance of abnormal DNA methylation in IBD-related carcinogenesis. Our study aimed to define methylation patterns in patients with a colonic cancer or dysplasia diagnosis following an IBD diagnosis. Multicentric cross-sectional study- 91 samples from colonic mucosa with/without dysplasia from 9 patients with IBD-related dysplasia/cancer and 26 patients with IBD and sporadic dysplasia/cancer were included. Methylation patterns of CpG islands in the promoter regions of 67 genes were studied by Methylation-specific Multiplex Ligation-dependent Probe Amplification. Mean age at IBD diagnosis: 42±16 years; at dysplasia diagnosis: 56± ± 14 years. Twenty-nine patients had ulcerative colitis. Twenty-five patients had at least 1 lesion endoscopically described as adenoma-like, 4 at least 1 non-adenoma like, 3 had cancer and 3 had dysplasia in flat mucosa. No patient had both adenoma-like and non-adenoma-like lesions. Patients with an IBD-related lesion were significantly younger at IBD diagnosis (p = 0.003) and at dysplasia/cancer diagnosis (p = 0.039). Promoter methylation of IGF2, RARB, ESR1, CHFR, CDH13, WT1, GATA5, WIF1 genes was significantly associated to dysplasia/cancer; methylation of MSH6, TIMP3 was significantly associated to IBD-related dysplasia/cancer. Promoter methylation of MSH6, MSH3, RUNX3, CRABP1, TP73, RARB, CDH13, PAX5, WT1, THBS1, TP53, SFRP1, WIF1, APAF1, BCL2 genes was significantly associated to active IBD. Methylation analysis, namely of MSH6, may contribute to the classification of dysplastic lesions in IBD– to be further tested in prospective studies.
- Open Access
- 10 January 2020
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 27 (5) , 304-311
Predictive Factors and Clinical Impact of Deep Remission in Celiac Disease
Introduction: The ultimate indicator of adherence to a gluten-free diet is the demonstration of mucosal healing. However, the need for histological reassessment is subject to controversy among “experts”. The aim of this study was to evaluate celiac patients who underwent histological reevaluation after starting a gluten-free diet in order to identify those with histological remission and associated factors. Methods: This retrospective study included patients who agreed to a histological reassessment after apparent clinical and serological remission and reported at least 12 months of diet adherence. In all cases, informed consent was signed for upper endoscopy. Results: A total of 69 patients were included. In 67.9% of cases, the diagnosis was made in the context of “classic” symptomatology, 17% had “nonclassical” presentation, and 15.1% were in latent phase. 69.2% of the diagnoses were initially suspected by serology. Endoscopically, 11.8% of the patients did not present suggestive features macroscopically, and a histological grade of Marsh IIIa–c was observed in 75.5% of all cases. The histological findings were normalized in 37.7%, which was associated with the presence of lower Marsh score values at diagnosis (p = 0.014) and lower DEXA T-score values (p = 0.038). A histological improvement was observed in 55 patients (≥2 grades in 37 cases), which was related to the initial transferrin saturation (p = 0.027) and with higher Marsh scores at diagnosis (p = 0.007). Conclusion: Even under a gluten-free diet, celiac histology normalization is difficult to obtain and appears to be independent of most clinical and serological findings at diagnosis. Patients with less severe histological levels at diagnosis reach remission more easily, but only represent the minority of the population.
- 10 January 2020
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 27 (5) , 304-311
Open AccessPredictive Factors and Clinical Impact of Deep Remission in Celiac Disease
Introduction: The ultimate indicator of adherence to a gluten-free diet is the demonstration of mucosal healing. However, the need for histological reassessment is subject to controversy among “experts”. The aim of this study was to evaluate celiac patients who underwent histological reevaluation after starting a gluten-free diet in order to identify those with histological remission and associated factors. Methods: This retrospective study included patients who agreed to a histological reassessment after apparent clinical and serological remission and reported at least 12 months of diet adherence. In all cases, informed consent was signed for upper endoscopy. Results: A total of 69 patients were included. In 67.9% of cases, the diagnosis was made in the context of “classic” symptomatology, 17% had “nonclassical” presentation, and 15.1% were in latent phase. 69.2% of the diagnoses were initially suspected by serology. Endoscopically, 11.8% of the patients did not present suggestive features macroscopically, and a histological grade of Marsh IIIa–c was observed in 75.5% of all cases. The histological findings were normalized in 37.7%, which was associated with the presence of lower Marsh score values at diagnosis (p = 0.014) and lower DEXA T-score values (p = 0.038). A histological improvement was observed in 55 patients (≥2 grades in 37 cases), which was related to the initial transferrin saturation (p = 0.027) and with higher Marsh scores at diagnosis (p = 0.007). Conclusion: Even under a gluten-free diet, celiac histology normalization is difficult to obtain and appears to be independent of most clinical and serological findings at diagnosis. Patients with less severe histological levels at diagnosis reach remission more easily, but only represent the minority of the population.